Yesterday it was reported that the CFO of Corcept Therapeutics Inc (CORT), Gary Charles Robb, exercised options to sell 25,000 CORT shares at $1.92 a share, for a total transaction value of $475K.
Following Gary Charles Robb’s last CORT Sell transaction on May 08, 2017, the stock climbed by 6.8%. In addition to Gary Charles Robb, 2 other CORT executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Corcept Therapeutics Inc’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $64.45 million and quarterly net profit of $17.75 million. In comparison, last year the company earned revenue of $42.76 million and had a net profit of $13.76 million. CORT’s market cap is $1.86B and the company has a P/E ratio of 13.53. Currently, Corcept Therapeutics Inc has an average volume of 2.84M.
In the last 30 days, insiders have sold $4.6M worth of CORT shares and purchased $1.27M worth of CORT shares. The insider sentiment on Corcept Therapeutics Inc has been positive according to 24 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Corcept Therapeutics, Inc. engages in the development of drugs for the treatment of severe psychiatric, neurological, and metabolic disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K.
